Moleculin Biotech, Inc.
Business
Moleculin Biotech is a late-stage pharmaceutical development company advancing Annamycin, a next-generation anthracycline in a pivotal Phase 3 trial (MIRACLE) for relapsed/refractory acute myeloid leukemia combined with cytarabine, with interim data expected mid-2026. The company also develops three technology portfolios—WP1066 (p-STAT3 inhibitors for brain tumors), WP1122 (glycolysis inhibitors for cancers and viruses), and additional Annamycin indications—funded through internal trials and investigator-initiated studies at academic institutions. Products are licensed from the University of Texas MD Anderson Cancer Center and are in Phase 1–3 clinical development across multiple cancer types and geographies.
Summary from 10-K filed 2026-03-18
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and development | 16 | 18 | 19 | 19 | 14 | |
| General and administrative | 9 | 9 | 10 | 12 | 8 | |
| Depreciation and amortization | 90,000 | 126,000 | 127,000 | 130,000 | 164,000 | |
| Total operating expenses | 25 | 27 | 30 | 31 | 23 | |
| Loss from operations | −25 | −27 | −30 | −31 | −23 | |
| Gain from change in fair value of warrant liabilities | 24 | 0 | −1 | 1 | 7 | |
| Loss on issuance of warrant liabilities | −31 | 0 | 0 | — | — | |
| Transaction costs allocated to warrant liabilities | −1 | 0 | −510,000 | 0 | — | |
| Loss on extinguishment of warrant liabilities | −614,000 | 0 | — | — | — | |
| Other (expense) income, net | −20,000 | 43,000 | 48,000 | 40,000 | 40,000 | |
| Interest income, net | 105,000 | 550,000 | 1 | 240,000 | — | |
| Net loss | −34 | −26 | −30 | −29 | −16 | |
| Warrant deemed dividend | −104,000 | 0 | — | — | — | |
| Net loss available to common stockholders | −34 | −26 | — | — | — | |
| Net loss per common share - basic and diluted (in dollars per share) | −28.42 | −189.14 | −15.07 | −15.22 | −0.59 | |
| Weighted average common shares outstanding, basic and diluted (in shares) | 1 | 137,720 | 2 | 2 | 27 | |
| Foreign currency translation | 51,000 | −32,000 | −21,000 | −29,000 | −24,000 | |
| Comprehensive loss | −34 | −26 | −30 | −29 | −16 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2025 2025-05-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 9 | — | 4 | 24 | 43 | |
| Prepaid expenses and other current assets | 808,000 | — | 916,000 | 3 | 2 | |
| Total current assets | 10 | — | 5 | 26 | 46 | |
| Furniture and equipment, net | 78,000 | — | 159,000 | 272,000 | 275,000 | |
| Intangible assets | 11 | — | 11 | 11 | 11 | |
| Other non-current assets | 900,000 | 900,000 | 0 | — | — | |
| Operating lease right-of-use asset | 314,000 | — | 424,000 | 524,000 | 403,000 | |
| Total Assets | 22 | — | 17 | 38 | 57 | |
| Accounts payable | 4 | — | 2 | 2 | 2 | |
| Accrued expenses and other current liabilities | 3 | — | 3 | 4 | 3 | |
| Total current liabilities | 7 | — | 5 | 7 | 5 | |
| Operating lease liability - long-term, net of current portion | 222,000 | — | 358,000 | 474,000 | 335,000 | |
| Warrant liability | 44,000 | — | 0 | 5 | 77,000 | |
| Total Liabilities | 7 | — | 6 | 12 | 5 | |
| Commitments and contingencies (Note 8) | — | — | — | — | — | |
| Preferred stock, $0.001 par value; 5,000,000 authorized shares, no shares issued or outstanding | 0 | — | 0 | 0 | 0 | |
| Common stock, $0.001 par value; 500,000,000 and 100,000,000 authorized shares as of December 31, 2025 and December 31, 2024, respectively, 3,199,228 and 135,155 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 3,000 | — | 0 | 33,000 | 29,000 | |
| Additional paid-in capital | 221 | — | 184 | 158 | 154 | |
| Accumulated other comprehensive income (loss) | 10,000 | — | −41,000 | — | — | |
| Accumulated deficit | −206 | — | −172 | −146 | −102 | |
| Total stockholders' equity | 15 | — | 11 | 31 | 52 | |
| Total liabilities and stockholders' equity | 22 | — | 17 | 38 | 57 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 2 | 2 | 2 | 2 | 2 | |
| Transaction costs allocated to warrant liabilities | 1 | 0 | 510,000 | 0 | — | |
| Operating lease, net | −26,000 | 103,000 | 119,000 | 92,000 | 96,000 | |
| Prepaid expenses and other assets | −792,000 | 2 | −272,000 | −857,000 | 431,000 | |
| Accounts payable | 1 | −468,000 | 403,000 | 731,000 | 235,000 | |
| Accrued expenses and other liabilities | 17,000 | −1 | 1 | 350,000 | 372,000 | |
| Net cash used in operating activities | −23 | −24 | −24 | −28 | −19 | |
| Purchase of fixed assets | 0 | −13,000 | −124,000 | −67,000 | −19,000 | |
| Net cash used in investing activities | 0 | −13,000 | −124,000 | −67,000 | −19,000 | |
| Proceeds from sale of common stock, pre-funded and common warrants and warrant inducement, net of issuance and transaction costs | 26 | 5 | 4 | — | — | |
| Proceeds from exercise of warrants | 2 | 1,000 | 0 | 0 | 63,000 | |
| Payment of tax liability for vested restricted stock units | −8,000 | −26,000 | −25,000 | −23,000 | −23,000 | |
| Net cash provided by financing activities | 27 | 5 | 4 | −23,000 | 75 | |
| Net increase (decrease) in cash and cash equivalents | 5 | −19 | −20 | −28 | 56 | |
| Effect of exchange rate changes on cash and cash equivalents | 51,000 | −32,000 | −21,000 | −29,000 | −24,000 | |
| Reclassification of warrant liabilities to equity pursuant to warrant amendments | 17 | 0 | — | — | — | |
| Equity warrants issued in relation to liability-classified warrant inducements | 6 | 0 | — | — | — | |
| Offering costs included in accounts payable and accrued liabilities | 138,000 | 0 | 115,000 | 0 | — | |
| Deemed dividend in connection with warrant amendment | 104,000 | 0 | — | — | — | |
| Transaction costs related to the sale of common stock, pre-funded and common warrants | 0 | 156,000 | 0 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Moleculin Biotech, Inc.'s CIK number?
Moleculin Biotech, Inc.'s SEC CIK number is 0001659617 (1659617). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Moleculin Biotech, Inc.'s SEC filings?
All of Moleculin Biotech, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Moleculin Biotech, Inc. last report earnings?
Moleculin Biotech, Inc. (MBRX) most recently filed an earnings 8-K with the SEC on May 15, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001437749-26-017226). This is Moleculin Biotech, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Moleculin Biotech, Inc.'s most recent earnings 8-K?
Moleculin Biotech, Inc.'s latest earnings 8-K (Item 2.02) was filed May 15, 2026 under accession 0001437749-26-017226. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Moleculin Biotech, Inc.'s latest earnings 8-K →
Look up any company's CIK number →